Découvrez nos professeurs et professeures!

Yves Fradet

Médecin clinicien enseignant titulaire

Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :
Ce profil n’a pas encore été complété.

Contribution à la recherche

Projets de recherche

  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2021-10-01 au 2026-09-30
  • Testing of Biological Activity of DPX-Survivac in vivo in HLA-A1 and HLA-B7 mice - ImmunoVaccine Technologies Inc., chercheur principal - 2020-11-20 au 2025-12-25
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • ÉTUDE DE LA RELATION ENTRE HABITUDES DE VIE, BIOMARQUEURS ET RISQUE DE CANCER DE LA PROSTATE - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2022-03-03 au 2024-05-01
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers - The W. Garfield Weston Foundation - Transformational Research, co-chercheur - 2020-06-01 au 2023-05-31
  • Biobanque en urologie - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-03-03 au 2023-05-01
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines - Fondation du CHU de Québec, chercheur principal - 2022-03-22 au 2023-03-21
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer - Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Société canadienne du cancer - Initiative SCC/IC-IRSC en prévention primaire du cancer, co-chercheur - 2022-01-15 au 2023-01-14
  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate - Merck Canada Inc., Consortium québécois sur la découverte du médicament, Fondation du CHU de Québec - Quantum Leap, chercheur principal - 2019-12-01 au 2022-11-30
  • Intégration de l'imagerie par résonance magnétique multiparamétrique dans la trajectoire diagnostique des patients avec suspicion de cancer de la prostate au CHU de Québec - Université Laval - Ministère de l'Économie et de l'Innovation - Programme de soutien aux organismes de recherche et d’innovation (PSO) - Volet 2 : Soutien aux projets, co-chercheur - 2020-06-15 au 2022-09-30
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer - The W. Garfield Weston Foundation, co-chercheur - 2020-09-01 au 2022-08-31
  • Identification des anomalies génétiques du cancer de la prostate et de leur impact clinique - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-04-01 au 2022-03-31
  • Développement d'une nouvelle thérapie d'activation de cellules T combinant des peptides MAGE-A9 et survivine utilisant la plateforme DPX d'IMV pour évaluer son activité préclinique et clinique dans le cancer de la vessie - Consortium québécois sur la découverte du médicament, ImmunoVaccine Technologies Inc., Fondation du CHU de Québec - Programme conjoint CQDM/Alsace BioValley, chercheur principal - 2019-04-01 au 2022-03-31
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer - Instituts de recherche en santé du Canada - Subvention Projet, University of British Columbia, co-chercheur - 2017-04-01 au 2022-03-31
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-02-17 au 2022-02-16
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions. - Société de recherche sur le cancer - Compétition GRePEC (SRC/FRSQ/MDEIE), co-chercheur - 2012-10-01 au 2021-12-31
  • Testing of Biological Activity of DPX-Survivac in vivo in HLA-A1, HLA-A24 and HLA-B7 Transgenic mice - ImmunoVaccine Technologies Inc., chercheur principal - 2021-05-28 au 2021-11-27
  • Effets d'une supplémentation riche en oméga-3 (MAG-EPA) sur le micro-environnement tumoral prostatique. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2020-11-01 au 2021-10-31
  • Prebiotics to enhance immunotherapy response in bladder cancer - The W. Garfield Weston Foundation - 2018 Proof-of-Principle Grant Call, chercheur principal - 2019-01-01 au 2021-07-31
  • Bourse de doctorat pour le projet de recherche de madame Fahimed Aeineh Negin - Fondation du CHU de Québec, chercheur principal - 2020-05-08 au 2021-05-07
  • Traitement du cancer de la prostate localisé par une approche immunothérapeutiquebasée - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2020-05-28 au 2021-03-31
  • projet de recherche en urologie (don dédié de la compagnie Tersera) - Fondation du CHU de Québec, chercheur principal - 2020-03-16 au 2021-03-15
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management - Instituts de recherche en santé du Canada - Fonctionnement: Subvention de promotion de l’impact - CCREES, co-chercheur - 2017-10-01 au 2020-09-30

Publications

  • Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials., Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Grivas P, Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10.1158/1078-0432.ccr-21-3089
  • Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial., Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, GALAHAD investigators, The Lancet. Oncology, 2022, 10.1016/s1470-2045(21)00757-9
  • A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota., Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Routy B, Cancer discovery, 2022, 10.1158/2159-8290.cd-21-0808
  • Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21
  • Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype., Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P, Clinical and translational medicine, 2022, 10.1002/ctm2.581
  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy., Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V, Clinical nutrition ESPEN, 2021, 10.1016/j.clnesp.2021.12.011
  • Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate., Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D, Cancers, 2021, 10.3390/cancers13246243
  • Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens., Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Leblond F, Journal of biomedical optics, 2021, 10.1117/1.jbo.26.11.116501
  • Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
  • Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA., Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P, International journal of molecular sciences, 2021, 10.3390/ijms22189757
  • Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7599
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial., Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, KEYNOTE-361 Investigators, The Lancet. Oncology, 2021, 10.1016/s1470-2045(21)00152-2
  • Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression., Vittrant B, Bergeron A, Molina OE, Leclercq M, Légaré XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A, Oncoimmunology, 2020, 10.1080/2162402x.2020.1851950
  • Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity., Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier É, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V, Molecular cancer research : MCR, 2020, 10.1158/1541-7786.mcr-20-0316
  • Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer., Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A, Frontiers in genetics, 2020, 10.3389/fgene.2020.550894
  • Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth., Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V, Prostaglandins, leukotrienes, and essential fatty acids, 2020, 10.1016/j.plefa.2020.102215
  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Pouliot F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • Building a Canadian Translational Bladder Cancer Research Network., Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC, Canadian Bladder Cancer Research Network, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6887
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial., Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, DANUBE study investigators, The Lancet. Oncology, 2020, 10.1016/s1470-2045(20)30541-6
  • Northeastern Section of the AUA 72nd Annual Meeting Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation., Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Trudel D, PLoS medicine, 2020, 10.1371/journal.pmed.1003281
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival., Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y, World journal of urology, 2020, 10.1007/s00345-020-03358-x
  • Message from our President, Zorn K, Bhojani N, Elterman D, Goldenberg S, So A, Paterson R, Desai M, Roehrborn R, Kaplan S, Gilling P, Berto F, Wang Z, Bjazevic J, Filler G, Romao R, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression., Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Guillemette C, British journal of cancer, 2020, 10.1038/s41416-020-0749-2
  • Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study., Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Pinthus J, The Journal of urology, 2020, 10.1097/ju.0000000000000714
  • Genome-wide germline correlates of the epigenetic landscape of prostate cancer., Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Boutros PC, Nature medicine, 2019, 10.1038/s41591-019-0579-z
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients., Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P, The Prostate, 2019, 10.1002/pros.23901
  • Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P, Clinical genitourinary cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up., Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Bajorin DF, Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 10.1093/annonc/mdz127
  • Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer., Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, TITAN Investigators, The New England journal of medicine, 2019, 10.1056/nejmoa1903307
  • Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data., Leclercq M, Vittrant B, Martin-Magniette ML, Scott Boyer MP, Perin O, Bergeron A, Fradet Y, Droit A, Frontiers in genetics, 2019, 10.3389/fgene.2019.00452
  • Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate., Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Trudel D, Radiation oncology (London, England), 2019, 10.1186/s13014-019-1267-3
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017
  • A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer., Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-18-1002
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F, Endocrine connections, 2019, 10.1530/ec-18-0476
  • Widespread and Functional RNA Circularization in Localized Prostate Cancer., Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, He HH, Cell, 2019, 10.1016/j.cell.2019.01.025
  • Canadian Urological Association guideline: Muscle-invasive bladder cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.5902
  • A Festschrift in Honor of Edward M. Messing, MD, FACS., Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Trump D, Bladder cancer (Amsterdam, Netherlands), 2018, 10.3233/blc-189037
  • Abstraits AUQ 2018, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice., Gevariya N, Besançon M, Robitaille K, Picard V, Diabaté L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V, The Prostate, 2018, 10.1002/pros.23706
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial., Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L, Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 10.1158/1078-0432.ccr-18-1187
  • 2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer., Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P, Urologic oncology, 2018, 10.1016/j.urolonc.2018.05.004
  • Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma., Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Black PC, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5377
  • Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer., Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, de Wit R, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10.1200/jco.2017.76.9562
  • Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting., Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Black PC, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5246
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival., Trinh VQ, Sirois J, Benzerdjeb N, Mansoori BK, Grosset AA, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Ladouceur M, Fradet Y, Saad F, Trudel D, The Prostate, 2018, 10.1002/pros.23513
  • Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review., Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4471
  • ABSTRAITS AUQ 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4968
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y, BJU international, 2017, 10.1111/bju.14041
  • Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study., Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V, Nutrition and cancer, 2017, 10.1080/01635581.2017.1367941
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • 2017 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017
  • Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer., Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, LATITUDE Investigators, The New England journal of medicine, 2017, 10.1056/nejmoa1704174
  • A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies., Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Bristow RG, European urology, 2017, 10.1016/j.eururo.2017.04.034
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma., Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, KEYNOTE-045 Investigators, The New England journal of medicine, 2017, 10.1056/nejmoa1613683
  • Genomic hallmarks of localized, non-indolent prostate cancer., Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Boutros PC, Nature, 2017, 10.1038/nature20788
  • Quality indicators in the management of bladder cancer: A modified Delphi study., Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Kassouf W, Urologic oncology, 2017, 10.1016/j.urolonc.2016.12.003
  • Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F, Scientific reports, 2016, 10.1038/srep37381
  • Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors., Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Boutros PC, European urology, 2016, 10.1016/j.eururo.2016.10.013
  • Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F, Scientific reports, 2016, 10.1038/srep33968
  • Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer., Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foley R, Cancer immunology research, 2016, 10.1158/2326-6066.cir-15-0189
  • 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts : National Harbor, MD, USA. 9-13 November 2016, , Journal for immunotherapy of cancer, 2016
  • A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer., Neveu B, Jain P, Têtu B, Wu L, Fradet Y, Pouliot F, Oncotarget, 2016, 10.18632/oncotarget.6360
  • Abstraits AUQ 2016 Programme Scientifique - Session 1, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Moderated Poster Session I: Oncology Thursday, September 29, 2016 10:15 am – 12:00 pm, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer., Ayari C, Besançon M, Bergeron A, LaRue H, Bussières V, Fradet Y, Cancer immunology, immunotherapy : CII, 2016, 10.1007/s00262-015-1789-y
  • Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015., Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Siemens DR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016, 10.5489/cuaj.3583
  • Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C, Cancer prevention research (Philadelphia, Pa.), 2015, 10.1158/1940-6207.capr-15-0069
  • The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression., Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E, European urology, 2015, 10.1016/j.eururo.2015.06.054
  • Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy., Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V, Diagnostic pathology, 2015, 10.1186/s13000-015-0294-0
  • Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302., Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Ryan CJ, European urology, 2015, 10.1016/j.eururo.2015.04.032
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Wu L, Cancer research, 2015, 10.1158/0008-5472.can-14-0992
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]., Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Shariat SF, European urology, 2015, 10.1016/j.eururo.2015.02.007
  • 2015 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • 2015 NS-AUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study., Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, COU-AA-302 Investigators, The Lancet. Oncology, 2015, 10.1016/s1470-2045(14)71205-7
  • Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis., Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M, Biomarkers in medicine, 2015, 10.2217/bmm.14.115
  • Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus., Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Shariat SF, Urologia internationalis, 2014, 10.1159/000369357
  • Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis., Gill S, Haince JF, Shi Q, Pavey ES, Beaudry G, Sargent DJ, Fradet Y, Clinical colorectal cancer, 2014, 10.1016/j.clcc.2014.12.005
  • The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy., Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C, Endocrine-related cancer, 2014, 10.1530/erc-14-0423
  • The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence., Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014, 10.5489/cuaj.1985
  • An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study., Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J, Prostate cancer and prostatic diseases, 2014, 10.1038/pcan.2014.24
  • Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study., Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, Clancy TE, Pipas JM, Resnick MB, Meyers MO, Wu TT, Huntsman D, Validire P, Farooq U, Fradet Y, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2659
  • IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness., Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V, Research and reports in urology, 2014, 10.2147/rru.s58643
  • Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer., Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY, International journal of cancer, 2014, 10.1002/ijc.28904
  • Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway., Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2567
  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)., Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Saad F, European urology, 2014, 10.1016/j.eururo.2014.02.056
  • 2014 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration., Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Kassouf W, Urologic oncology, 2014, 10.1016/j.urolonc.2013.10.016
  • Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis., Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Svatek RS, Urology, 2014, 10.1016/j.urology.2013.10.060
  • Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes., Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Shariat SF, BJU international, 2014, 10.1111/bju.12121
  • Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients., Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Shariat SF, European urology, 2013, 10.1016/j.eururo.2013.11.040
  • Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer., Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Saad F, Bell D, Drachenberg D, Kassouf W, World journal of urology, 2013, 10.1007/s00345-013-1207-z
  • Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer., Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 10.1158/1078-0432.ccr-13-1100
  • Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system., Bachir BG, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.201
  • Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time., Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Kassouf W, European urology, 2013, 10.1016/j.eururo.2013.09.050
  • Toll-like receptors in urothelial cells--targets for cancer immunotherapy., LaRue H, Ayari C, Bergeron A, Fradet Y, Nature reviews. Urology, 2013, 10.1038/nrurol.2013.153
  • Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma., Fairey AS, Jacobsen NE, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Kassouf W, European urology, 2013, 10.1016/j.eururo.2013.06.014
  • High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer., Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu B, Fradet V, Fradet Y, Human pathology, 2013, 10.1016/j.humpath.2013.01.014
  • Lymphadenectomy for bladder cancer at the time of radical cystectomy., Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH, European urology, 2013, 10.1016/j.eururo.2013.04.036
  • Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data., Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D, European urology, 2013, 10.1016/j.eururo.2013.03.059
  • Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy., Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Shariat SF, European journal of cancer (Oxford, England : 1990), 2013, 10.1016/j.ejca.2013.02.001
  • Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome., Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Kassouf W, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.014
  • Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma., Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Izawa JI, Urologic oncology, 2013, 10.1016/j.urolonc.2011.12.004
  • Abstraits AUQ 2013, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013
  • Abiraterone in metastatic prostate cancer without previous chemotherapy., Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, COU-AA-302 Investigators, The New England journal of medicine, 2012, 10.1056/nejmoa1209096
  • Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort., Power NE, Kassouf W, Bell D, Aprikian AG, Fradet Y, Lacombe L, Chin J, Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf JB, Drachenberg D, Rendon RA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11012
  • Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?, Kotb AF, Kovac E, Kassouf W, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Aprikian AG, World journal of urology, 2012, 10.1007/s00345-012-0832-2
  • Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada., Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, Black P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12146
  • Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration., Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Jacobsen NE, BJU international, 2012, 10.1111/j.1464-410x.2012.11474.x
  • Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression., Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 10.1158/1078-0432.ccr-12-2812
  • Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that is the question., Mauermann J, Fradet V, Fradet Y, European urology, 2012, 10.1016/j.eururo.2012.10.047
  • Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling., Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Shariat SF, British journal of cancer, 2012, 10.1038/bjc.2012.464
  • Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12272
  • A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study., Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium, European urology, 2012, 10.1016/j.eururo.2012.09.007
  • Predictors of cancer-specific mortality after disease recurrence following radical cystectomy., Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Bladder Cancer Research Consortium, BJU international, 2012, 10.1111/j.1464-410x.2012.11433.x
  • Northeastern Section of the American Urological Association 64(th) Annual Meeting, Niagara Falls, Ontario Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients., Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y, European urology, 2012, 10.1016/j.eururo.2012.08.002
  • Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?, Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Svatek RS, World journal of urology, 2012, 10.1007/s00345-012-0910-5
  • Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay., Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Chun FK, European urology, 2012, 10.1016/j.eururo.2012.07.030
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience., Sandhu GS, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Kassouf W, Drachenberg D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11276
  • Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy., Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M, The Journal of urology, 2012, 10.1016/j.juro.2012.03.007
  • Canadian Consensus Conference: The FDA decision on the use of 5ARIs., Klotz L, Chetner M, Chin J, Finelli T, Fleshner N, Fradet Y, Goldenberg L, Nickel JC, Siemens R, So A, Sugar L, Zlotta A, Klein E, Parnes H, Penson D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12058
  • Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience., Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W, BJU international, 2012, 10.1111/j.1464-410x.2012.11133.x
  • Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro., Fradet Y, The Journal of urology, 2012, 10.1016/j.juro.2012.02.2563
  • Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery., Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Upper Tract Urothelial Carcinoma Collaboration (UTUCC), European urology, 2012, 10.1016/j.eururo.2012.02.018
  • The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience., Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Saad F, Matsumoto E, Rendon RA, Urology, 2012, 10.1016/j.urology.2011.11.058
  • Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy., Lodde M, Lacombe L, Naselli A, Puppo P, Mian M, Fradet Y, World journal of urology, 2012, 10.1007/s00345-012-0827-z
  • Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers., Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Lotan Y, The Journal of urology, 2011, 10.1016/j.juro.2011.10.031
  • The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy., Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É, European urology, 2011, 10.1016/j.eururo.2011.12.021
  • Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment., Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Gonen M, European urology, 2011, 10.1016/j.eururo.2011.10.011
  • Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy., Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Shariat SF, World journal of urology, 2011, 10.1007/s00345-011-0772-2
  • Northeastern Section of the American Urological Association 63(rd) Annual Meeting, New Orleans, Louisiana October 26 - 30, 2011 Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database., Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP, Urologic oncology, 2011, 10.1016/j.urolonc.2011.07.014
  • Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA., Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Chinnaiyan AM, Science translational medicine, 2011, 10.1126/scitranslmed.3001970
  • Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer., Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Lévesque E, The Journal of clinical endocrinology and metabolism, 2011, 10.1210/jc.2011-1049
  • 2011 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery., Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Shariat SF, Urologia internationalis, 2011, 10.1159/000325463
  • SRD5A polymorphisms and biochemical failure after radical prostatectomy., Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E, European urology, 2011, 10.1016/j.eururo.2011.06.020
  • Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis., Sargent DJ, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy T, Gill S, Siemons GO, Shi Q, Bot BM, Wu TT, Beaudry G, Haince JF, Fradet Y, Annals of surgical oncology, 2011, 10.1245/s10434-011-1731-2
  • Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder., Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Skinner EC, Urologic oncology, 2011, 10.1016/j.urolonc.2011.02.011
  • Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience., Chalasani V, Kassouf W, Chin JL, Fradet Y, Aprikian AG, Fairey AS, Estey E, Lacombe L, Rendon R, Bell D, Cagiannos I, Drachenberg D, Lattouf JB, Izawa JI, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10040
  • Toll-like receptors in normal and malignant human bladders., Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y, The Journal of urology, 2011, 10.1016/j.juro.2010.12.097
  • Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy., Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Shariat SF, The Journal of urology, 2011, 10.1016/j.juro.2010.11.082
  • A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment., Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D, The Lancet. Oncology, 2011, 10.1016/s1470-2045(10)70296-5
  • Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort., Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Dinney CP, BJU international, 2011, 10.1111/j.1464-410x.2010.09628.x
  • Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience., Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Kassouf W, BJU international, 2010, 10.1111/j.1464-410x.2010.09912.x
  • Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer., Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2010.09.110
  • Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2., Aziz A, Lessard A, Moore K, Hovington H, Latulippe E, Larue H, Fradet Y, Lacombe L, BJU international, 2010, 10.1111/j.1464-410x.2010.09909.x
  • Dual-kidney transplants as an alternative for very marginal donors: long-term follow-up in 63 patients., De Serres SA, Caumartin Y, Noël R, Lachance JG, Côté I, Naud A, Fradet Y, Mfarrej BG, Agharazii M, Houde I, Transplantation, 2010, 10.1097/tp.0b013e3181f8f2b8
  • Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy., Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Shariat SF, BJU international, 2010, 10.1111/j.1464-410x.2010.09902.x
  • 2010 NS-AUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma., Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y, BJU international, 2010, 10.1111/j.1464-410x.2010.09212.x
  • Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer., Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB, The Journal of urology, 2010, 10.1016/j.juro.2010.06.148
  • Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis., Trudel D, Fradet Y, Meyer F, Têtu B, Human pathology, 2010, 10.1016/j.humpath.2010.05.001
  • Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients., Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2010.04.081
  • p53 immunohistochemistry in bladder cancer--a new approach to an old question., Goebell PJ, Groshen SG, Schmitz-Dräger BJ, International Study-Initiative on Bladder Cancer (ISBC), Urologic oncology, 2010, 10.1016/j.urolonc.2010.03.021
  • The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder., Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Dinney CP, Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, 10.1158/1078-0432.ccr-10-0457
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes., Haince JF, Houde M, Beaudry G, L'espérance S, Garon G, Desaulniers M, Hafer LJ, Heald JI, Lyle S, Grossman SR, Têtu B, Sargent DJ, Fradet Y, Journal of clinical pathology, 2010, 10.1136/jcp.2009.072983
  • pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder., Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2010.04.007
  • Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients., Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2010.02.021
  • BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress., Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y, Urologic oncology, 2010, 10.1016/j.urolonc.2009.07.026
  • Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer., Lodde M, Lacombe L, Fradet Y, Urology, 2010, 10.1016/j.urology.2009.12.057
  • International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy., Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Fradet Y, BJU international, 2010, 10.1111/j.1464-410x.2010.09217.x
  • Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients., Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2009.08.145
  • Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer., Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Lotan Y, The Journal of urology, 2010, 10.1016/j.juro.2009.08.115
  • Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome., Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Shariat SF, European urology, 2010, 10.1016/j.eururo.2010.01.015
  • Abstracts for CUAJ Bladder Cancer Supplement Volume 3, Issue 6, Supplement 4, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1181
  • Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach., Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH, International Bladder Cancer Nomogram Consortium, Cancer, 2009, 10.1002/cncr.24615
  • Screening for bladder cancer: the best opportunity to reduce mortality., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1192
  • Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study., Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y, Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, 10.1158/1078-0432.ccr-08-2554
  • 2009 AUA-NS Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort., Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Shariat SF, European urology, 2009, 10.1016/j.eururo.2009.09.024
  • High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer., Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y, International journal of cancer, 2009, 10.1002/ijc.24503
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality., Inman BA, Tran VT, Fradet Y, Lacombe L, Cancer, 2009, 10.1002/cncr.24339
  • p53 expression in patients with advanced urothelial cancer of the urinary bladder., Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Lotan Y, BJU international, 2009, 10.1111/j.1464-410x.2009.08742.x
  • p53 predictive value for pT1-2 N0 disease at radical cystectomy., Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Cote RJ, The Journal of urology, 2009, 10.1016/j.juro.2009.05.024
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Early detection of prostate cancer local recurrence by urinary prostate-specific antigen., Bolduc S, Inman BA, Lacombe L, Fradet Y, Tremblay RR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1074
  • Gleason grading controversies: what the chemoprevention trials have taught us., Klotz L, Drachenberg D, Fradet Y, Saad F, Trachtenberg J, Zlotta A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1115
  • Sharing the responsibility of prostate cancer risk reduction, Klotz L, Fradet Y, Goldenberg L, Tanguay S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • The burden of prostate cancer in Canada., Fradet Y, Klotz L, Trachtenberg J, Zlotta A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen., Fradet Y, Current opinion in urology, 2009, 10.1097/mou.0b013e32832a08b5
  • Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy., Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y, The Journal of urology, 2009, 10.1016/j.juro.2009.02.125
  • Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram., Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Haese A, European urology, 2009, 10.1016/j.eururo.2009.03.029
  • Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy., Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y, European urology, 2009, 10.1016/j.eururo.2009.01.040
  • Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer., Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Shariat SF, Journal of the National Cancer Institute, 2009, 10.1093/jnci/djn451
  • PROGRAMME SCIENTIFIQUE : Vendredi, le 14 novembre 2008, Session scientifique V, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • The detection of genetic markers of bladder cancer in urine and serum., Lodde M, Fradet Y, Current opinion in urology, 2008, 10.1097/mou.0b013e32830b86d1
  • Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?, Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L, Cancer, 2008, 10.1002/cncr.23627
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • The management of high-risk prostate cancer in 2008., Fradet Y, World journal of urology, 2008, 10.1007/s00345-008-0261-4
  • Invasive bladder cancer: time is of the essence., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008, 10.5489/cuaj.483
  • Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer., Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L, International journal of cancer, 2008, 10.1002/ijc.23240
  • Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin., Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, 10.1158/1078-0432.ccr-07-4475
  • Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry., Trudel D, Fradet Y, Meyer F, Harel F, Têtu B, Human pathology, 2008, 10.1016/j.humpath.2007.09.021
  • PCA3: a molecular urine assay for predicting prostate biopsy outcome., Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J, The Journal of urology, 2008, 10.1016/j.juro.2007.11.038
  • Substratification of high-risk localised prostate cancer treated by radical prostatectomy., Lodde M, Harel F, Lacombe L, Fradet Y, World journal of urology, 2008, 10.1007/s00345-008-0252-5
  • Bladder cancer markers in patient management: the current perspective., Schmitz-Dräger BJ, Fradet Y, Grossman HB, World journal of urology, 2007, 10.1007/s00345-007-0225-0
  • PROGRAMME SCIENTIFIQUE * SCIENTIFIC PROGRAM Association des urologues du QUébec * Qué Urological Association Congrès annuel * Annual Meeting 9 au 11 novembre 2007 * November 9-11, 2007 Hôtel Hyatt Regency Montréal Centre-Ville, Montréal PQ., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL., Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y, Tremblay RR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007, 10.5489/cuaj.444
  • Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization., Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2007, 10.1038/modpathol.3800963
  • Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES., Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Réfutation: Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate? : OUI, Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Canadian Urological Association 62nd Annual Meeting, Quebec City, QC, June 24-27, 2006., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate? : OUI, Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Should Canadians be offered systematic prostate cancer screening? Yes., Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study., Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ, PC B302/01 Study Group, The Journal of urology, 2007, 10.1016/j.juro.2007.03.028
  • A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer., Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ, PC B302/01 Study Group, The Journal of urology, 2007, 10.1016/j.juro.2007.03.034
  • MAGE-A9 mRNA and protein expression in bladder cancer., Picard V, Bergeron A, Larue H, Fradet Y, International journal of cancer, 2007, 10.1002/ijc.22282
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression., Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED, Cancer, 2007, 10.1002/cncr.22588
  • PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy., Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J, Urology, 2007, 10.1016/j.urology.2006.12.014
  • Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study., Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S, European urology, 2007, 10.1016/j.eururo.2007.01.031
  • Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer., Meyer F, Têtu B, Bairati I, Lacombe L, Fradet Y, The Canadian journal of urology, 2006
  • Cancer-testis antigen expression in bladder cancer., Fradet Y, Picard V, Bergeron A, LaRue H, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2006
  • Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature., Fradet Y, Aprikian A, Dranitsaris G, Siemens R, Tsihlias J, Fleshner N, Canadian surgical wait times (SWAT) initiative, The Canadian journal of urology, 2006
  • Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer., Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y, The Journal of urology, 2006, 10.1016/s0022-5347(05)00653-1
  • Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers., Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Droller MJ, Urology, 2005, 10.1016/j.urology.2005.08.064
  • Cancer-testis antigen expression in bladder cancer., Fradet Y, Picard V, Bergeron A, LaRue H, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005
  • Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers., Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Lokeshwar VB, Urology, 2005, 10.1016/j.urology.2005.08.065
  • Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery., Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L, Journal of pain and symptom management, 2005, 10.1016/j.jpainsymman.2005.05.011
  • Insomnia in men treated with radical prostatectomy for prostate cancer., Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y, Psycho-oncology, 2005, 10.1002/pon.830
  • ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma., Têtu B, Tiguert R, Harel F, Fradet Y, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2005, 10.1038/modpathol.3800262
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival., Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L, European urology, 2005, 10.1016/j.eururo.2004.12.015
  • uPM3, a new molecular urine test for the detection of prostate cancer., Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Mâsse B, Piché L, Chypre C, Urology, 2004, 10.1016/j.urology.2004.03.052
  • A survey of urological manpower, technology, and resources in Canada., Pommerville P, Goldenberg SL, Wilson JW, Fradet Y, Corcos J, Morris BA, The Canadian journal of urology, 2004
  • Accelerated induction of bladder cancer in patched heterozygous mutant mice., Hamed S, LaRue H, Hovington H, Girard J, Jeannotte L, Latulippe E, Fradet Y, Cancer research, 2004, 10.1158/0008-5472.can-03-2031
  • Safety and outcome of early catheter removal after radical retropubic prostatectomy., Tiguert R, Rigaud J, Fradet Y, Urology, 2004, 10.1016/j.urology.2003.10.042
  • Bicalutamide (Casodex) in the treatment of prostate cancer., Fradet Y, Expert review of anticancer therapy, 2004, 10.1586/14737140.4.1.37
  • Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy., Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y, The Prostate, 2004, 10.1002/pros.10329
  • Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction., Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J, Fradet Y, Lim G, Marrano P, Zielenska M, Squire JA, The American journal of pathology, 2004, 10.1016/s0002-9440(10)63118-5
  • Significance of MMP-2 expression in prostate cancer: an immunohistochemical study., Trudel D, Fradet Y, Meyer F, Harel F, Têtu B, Cancer research, 2003
  • Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients., Inman BA, Harel F, Tiguert R, Lacombe L, Fradet Y, The Journal of urology, 2003, 10.1097/01.ju.0000092500.68655.48
  • [The PATCHED/Sonic Hedgehog signalling pathway in superficial bladder cancer]., LaRue H, Simoneau M, Aboulkassim TO, Lemieux P, Girard J, Hamed S, Hovington H, Jeannotte L, Fradet Y, Medecine sciences : M/S, 2003, 10.1051/medsci/20031910920
  • Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy., Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S, Canadian Uro-Oncology Group, The Journal of urology, 2003, 10.1097/01.ju.0000081404.98273.fd
  • Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level., Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y, The Journal of urology, 2003, 10.1097/01.ju.0000075351.51838.b3
  • Alteration of the PATCHED locus in superficial bladder cancer., Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y, Oncogene, 2003, 10.1038/sj.onc.1206513
  • [Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer]., Rigaud J, Tiguert R, Fradet Y, Bouchot O, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002
  • [Molecular markers of infiltrating cancer of the bladder]., Rigaud J, Tiguert R, Fradet Y, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002
  • Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?, Grégoire M, Liandier F, Naud A, Lacombe L, Fradet Y, The Journal of urology, 2002, 10.1016/s0022-5347(05)64678-2
  • Controversies in the management of localized prostate cancer: consensus development by Canadian urologists., Klotz LH, Fradet Y, The Canadian journal of urology, 2002
  • Prognostic markers in muscle invasive bladder cancer., Tiguert R, Lessard A, So A, Fradet Y, World journal of urology, 2002, 10.1007/s00345-002-0279-y
  • Recent advances in the management of superficial bladder tumors., Fradet Y, The Canadian journal of urology, 2002
  • Role of radical prostatectomy in high-risk prostate cancer., Fradet Y, The Canadian journal of urology, 2002
  • New diagnostic and prognostic tools in bladder cancer., Tiguert R, Fradet Y, Current opinion in urology, 2002, 10.1097/00042307-200205000-00011
  • Identification of two genes differentially expressed upon different spatial configuration of the MGH-U3 human bladder cancer cells., Champetier S, Fradet Y, Bachvarov D, Urologic oncology, 2002, 10.1016/s1078-1439(01)00130-2
  • Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer., Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y, Urology, 2001, 10.1016/s0090-4295(01)01245-6
  • Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy., Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y, International journal of cancer, 2001, 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3
  • Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest., Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y, Oncogene, 2000, 10.1038/sj.onc.1204022
  • p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?, Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y, European urology, 2000, 10.1159/000020364
  • Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group., Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Moore R, Ernst S, Paton V, BJU international, 2000, 10.1046/j.1464-410x.2000.00880.x
  • [International Prostate Symptom Scale. Evaluation of the usefulness of a French version]., Moisan J, Grégoire JP, Labrecque MG, Fradet Y, Canadian family physician Medecin de famille canadien, 2000
  • Can biological markers predict recurrence and progression of superficial bladder cancer?, Fradet Y, Lacombe L, Current opinion in urology, 2000, 10.1097/00042307-200009000-00013
  • Lifetime occupational physical activity and incidental prostate cancer (Canada)., Bairati I, Larouche R, Meyer F, Moore L, Fradet Y, Cancer causes & control : CCC, 2000, 10.1023/a:1008936826337
  • Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network., McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM, Clinical cancer research : an official journal of the American Association for Cancer Research, 2000
  • Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis., Nam RK, Redelmeier DA, Spiess PE, Sampson HA, Fradet Y, Jewett MA, The Journal of urology, 2000, 10.1016/s0022-5347(05)67797-x
  • P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers., LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Têtu B, Fradet Y, Carcinogenesis, 2000, 10.1093/carcin/21.1.101
  • Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes., Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y, International journal of cancer, 2000, 10.1002/(sici)1097-0215(20000120)89:1<100::aid-ijc16>3.0.co;2-q
  • Use of markers in defining urothelial premalignant and malignant conditions., Grossman HB, Schmitz-Dräger B, Fradet Y, Tribukait B, Scandinavian journal of urology and nephrology. Supplementum, 2000, 10.1080/003655900750169347
  • Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure., Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y, The Journal of urology, 1999, 10.1016/s0022-5347(05)68092-5
  • Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence., Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y, Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
  • Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors., Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y, Human pathology, 1999, 10.1016/s0046-8177(99)90067-9
  • Dietary fat and prostate cancer survival., Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L, Cancer causes & control : CCC, 1999, 10.1023/a:1008913307947
  • Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence., Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C, The American journal of pathology, 1999, 10.1016/s0002-9440(10)65105-x
  • Low frequency of human papillomavirus infection in initial papillary bladder tumors., Simoneau M, LaRue H, Fradet Y, Urological research, 1999, 10.1007/s002400050107
  • Blood management and radical retropubic prostatectomy: Quebec experience., Lacombe L, Fradet Y, The Canadian journal of urology, 1999
  • CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group., Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplante S, Urology, 1999, 10.1016/s0090-4295(98)00616-5
  • Downward trend in prostate cancer mortality in Quebec and Canada., Meyer F, Moore L, Bairati I, Fradet Y, The Journal of urology, 1999, 10.1016/s0022-5347(01)61628-8
  • Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery., Jewett MA, Valiquette L, Sampson HA, Katz J, Fradet Y, Redelmeier DA, The Journal of urology, 1999, 10.1016/s0022-5347(01)61929-3
  • Dietary fat and prostate cancer progression and survival., Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L, European urology, 1999, 10.1159/000019913
  • Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31., Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y, Oncogene, 1999, 10.1038/sj.onc.1202277
  • Prostate cancer: 4. Screening., Meyer F, Fradet Y, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1998
  • Quebec prostate cancer mortality dropped in 1996., Meyer F, Moore L, Bairati I, Fradet Y, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1998
  • Genetic and molecular markers in the prognosis of bladder cancer., Fradet Y, Kubota Y, Schalken JA, Uchida T, Yoshida O, Urologic oncology, 1998, 10.1016/s1078-1439(99)00021-6
  • Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group., Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, De Porre P, Urology, 1998, 10.1016/s0090-4295(98)00129-0
  • Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network., Lianes P, Charytonowicz E, Cordon-Cardo C, Fradet Y, Grossman HB, Hemstreet GP, Waldman FM, Chew K, Wheeless LL, Faraggi D, Clinical cancer research : an official journal of the American Association for Cancer Research, 1998
  • The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index., Allard P, Bernard P, Fradet Y, Têtu B, British journal of urology, 1998, 10.1046/j.1464-410x.1998.00628.x
  • Dietary fat and advanced prostate cancer., Bairati I, Meyer F, Fradet Y, Moore L, The Journal of urology, 1998, 10.1016/s0022-5347(01)63579-1
  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group., Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A, The New England journal of medicine, 1998, 10.1056/nejm199804303381804
  • Phenotypic characterization of bladder cancer., Fradet Y, European urology, 1998, 10.1159/000052250
  • Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark., Fradet Y, Lockhard C, The Canadian journal of urology, 1997
  • Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer., LaRue H, Parent-Vaugeois C, Bergeron A, Champetier S, Fradet Y, International journal of cancer, 1997, 10.1002/(sici)1097-0215(19970611)71:6<986::aid-ijc14>3.0.co;2-4
  • The treatment of prostate cancer: how is failure defined and how can it be minimized?, Fradet Y, The Canadian journal of urology, 1997
  • Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors., Grégoire M, Fradet Y, Meyer F, Têtu B, Bois R, Bédard G, Charrois R, Naud A, The Journal of urology, 1997, 10.1016/s0022-5347(01)64827-4
  • Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder (by Harry W. Herr, MD, Carl M. Pinsky, MD, Willet F. Whitmore, Jr, MD, Herbert F. Oettgen, MD, and Myron R. Melamed, MD). 1983., Herr HW, Fradet Y, Klein FA, Seminars in urologic oncology, 1997
  • Neoadjuvant hormonal therapy: the Canadian experience., Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B, Urology, 1997, 10.1016/s0090-4295(97)00170-2
  • Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder., Lee E, Schwaibold H, Fradet Y, Huland E, Huland H, The Journal of urology, 1997, 10.1016/s0022-5347(01)65143-7
  • Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization., Bergeron A, LaRue H, Fradet Y, The Biochemical journal, 1997, 10.1042/bj3210889
  • Dietary energy and nutrients in relation to preclinical prostate cancer., Meyer F, Bairati I, Fradet Y, Moore L, Nutrition and cancer, 1997, 10.1080/01635589709514612
  • [Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]., Lacombe L, Gauthier J, Lafleur L, Fradet Y, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996
  • Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study., Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1996
  • The role of neoadjuvant androgen deprivation prior to radical prostatectomy., Fradet Y, The Urologic clinics of North America, 1996, 10.1016/s0094-0143(05)70337-2
  • Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer., Têtu B, Allard P, Fradet Y, Roberge N, Bernard P, Human pathology, 1996, 10.1016/s0046-8177(96)90219-1
  • Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group., Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S, The Journal of urology, 1996, 10.1016/s0022-5347(01)65645-3
  • Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies., Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Miles BJ, Urology, 1996, 10.1016/s0090-4295(96)00149-5
  • Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer., Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P, The Journal of urology, 1996, 10.1016/s0022-5347(01)66198-6
  • Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy., Van der Kwast TH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labrie F, The Prostate, 1996, 10.1002/(sici)1097-0045(199604)28:4<227::aid-pros3>3.0.co;2-a
  • A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia., Elhilali MM, Ramsey EW, Barkin J, Casey RW, Boake RC, Beland G, Fradet Y, Trachtenberg J, Orovan WL, Schick E, Klotz LH, Urology, 1996, 10.1016/s0090-4295(99)80449-x
  • MAUB is a new mucin antigen associated with bladder cancer., Bergeron A, Champetier S, LaRue H, Fradet Y, The Journal of biological chemistry, 1996, 10.1074/jbc.271.12.6933
  • Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211., Bergeron A, LaRue H, Fradet Y, Cancer research, 1996
  • Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line., Battelli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F, International journal of cancer, 1996, 10.1002/(sici)1097-0215(19960208)65:4<485::aid-ijc16>3.0.co;2-9
  • Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study., Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F, The American journal of surgical pathology, 1996, 10.1097/00000478-199601000-00010
  • [Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma]., Marois C, Bedard G, Charrois R, Fradet Y, Naud A, Gregoire M, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1995
  • Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder., Allard P, Fradet Y, Têtu B, Bernard P, Clinical cancer research : an official journal of the American Association for Cancer Research, 1995
  • The etiology of bladder cancer--are there any new clues or predictors of behavior?, Shirai T, Fradet Y, Huland H, Bollack C, Droller M, Janknegt R, Jones P, Kagawa S, International journal of urology : official journal of the Japanese Urological Association, 1995, 10.1111/j.1442-2042.1995.tb00481.x
  • Human papillomavirus in transitional cell carcinoma of the urinary bladder, LaRue H, Simoneau M, Fradet Y, Clinical cancer research : an official journal of the American Association for Cancer Research, 1995
  • Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy., Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B, Cancer surveys, 1995
  • Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer., Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y, Chopin DK, British journal of cancer, 1995, 10.1038/bjc.1995.40
  • Screening for prostate cancer: a urological perspective., Fradet Y, The Canadian journal of oncology, 1994
  • Influence of the diagnostic modality on the pathological stage of clinically localized prostatic cancer., Bellavance GB, Fradet Y, The Canadian journal of urology, 1994
  • Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study., Ooi A, Herz F, Ii S, Cordoncardo C, Fradet Y, Mayall B, International journal of oncology, 1994, 10.3892/ijo.4.1.85
  • Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial., Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Clinical and investigative medicine. Medecine clinique et experimentale, 1993
  • Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow., Chabanas A, Rambeaud JJ, Seigneurin D, Fradet Y, Lawrence JJ, Faure G, Cytometry, 1993, 10.1002/cyto.990140814
  • Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells., Bonner RB, Hemstreet GP, Fradet Y, Rao JY, Min KW, Hurst RE, Cancer, 1993, 10.1002/1097-0142(19931015)72:8<2461::aid-cncr2820720826>3.0.co;2-c
  • Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis., Rao JY, Hemstreet GP, Hurst RE, Bonner RB, Jones PL, Min KW, Fradet Y, Proceedings of the National Academy of Sciences of the United States of America, 1993, 10.1073/pnas.90.17.8287
  • Critical appraisal of tumor markers in bladder cancer., Fradet Y, Cordon-Cardo C, Seminars in urology, 1993
  • Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference., Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B, Cytometry, 1993, 10.1002/cyto.990140504
  • Cell surface differentiation antigens of normal urothelium and bladder tumors., Dalbagni G, Reuter VE, Sheinfeld J, Fradet Y, Fair WR, Cordon-Cardo C, Seminars in surgical oncology, 1992, 10.1002/ssu.2980080508
  • Radioimmunodetection of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies., Fradet Y, Friede J, Guertin B, Leclerc J, Dufour C, Caron C, The Journal of urology, 1992, 10.1016/s0022-5347(17)36620-x
  • Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies., de Harven E, Fradet Y, Connolly JG, Hanna W, He S, Wang Y, Choi BC, McGroarty R, Bootsma G, Tilups A, Cancer research, 1992
  • Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors., Cordon-Cardo C, Wartinger DD, Melamed MR, Fair W, Fradet Y, The American journal of pathology, 1992
  • Markers of prognosis in superficial bladder cancer., Fradet Y, Seminars in urology, 1992
  • Intermediate endpoint biomarkers for chemoprevention., Hemstreet GP, Rao JY, Hurst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ, Journal of cellular biochemistry. Supplement, 1992, 10.1002/jcb.240501320
  • Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder., Fradet Y, Lafleur L, LaRue H, Journal of cellular biochemistry. Supplement, 1992, 10.1002/jcb.240501319
  • Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder., Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ, The Journal of urology, 1991, 10.1016/s0022-5347(17)38202-2
  • Molecular and immunologic approaches in the management of bladder cancer., Fradet Y, The Urologic clinics of North America, 1991
  • Contemporary Management of Bladder Cancer: Identifying patients who are at risk., Bell D, Fradet Y, Canadian family physician Medecin de famille canadien, 1991
  • Total androgen ablation: Canadian experience., Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD, The Urologic clinics of North America, 1991
  • DNA slit-scan flow cytometry of bladder irrigation specimens and the importance of recognizing urothelial cells., Wheeless LL, Reeder JE, O'Connell MJ, Robinson RD, Cosgriff JM, Fradet Y, Frank IN, Cockett AT, Cytometry, 1991, 10.1002/cyto.990120207
  • Precision of DNA flow cytometry in inter-institutional analyses., Wheeless LL, Coon JS, Cox C, Deitch AD, deVere White RW, Fradet Y, Koss LG, Melamed MR, O'Connell MJ, Reeder JE, Cytometry, 1991, 10.1002/cyto.990120505
  • Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas., Fradet Y, LaRue H, Parent-Vaugeois C, Bergeron A, Dufour C, Boucher L, Bernier L, International journal of cancer, 1990, 10.1002/ijc.2910460607
  • Biological markers of prognosis in invasive bladder cancer., Fradet Y, Seminars in oncology, 1990
  • A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma., Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD, Cancer, 1990, 10.1002/cncr.1990.66.s5.1074
  • The assessment of disease aggressivity in stage D2 prostate cancer patients (review)., Koutsilieris M, Laroche B, Thabet M, Fradet Y, Anticancer research, 1990
  • Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group., Fradet Y, Tardif M, Bourget L, Robert J, Cancer research, 1990
  • Growth-regulated surface glycoproteins of human bladder cancer., Gauthier J, Fradet Y, Cancer research, 1990
  • Renal prostaglandins in postobstructive diuresis. Comparative study of unilateral and bilateral obstruction in conscious dogs., Fradet Y, Lebel M, Grose JH, Talbot J, Charrois R, Prostaglandins, leukotrienes, and essential fatty acids, 1988, 10.1016/0952-3278(88)90108-1
  • Total androgen blockade for metastatic cancer of the prostate., Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, American journal of clinical oncology, 1988, 10.1097/00000421-198801102-00043
  • Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies., Fradet Y, Islam N, Boucher L, Parent-Vaugeois C, Tardif M, Proceedings of the National Academy of Sciences of the United States of America, 1987, 10.1073/pnas.84.20.7227
  • Total androgen blockade vs orchiectomy in stage D2 prostate cancer., Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Venner PM, Tewari HD, Progress in clinical and biological research, 1987
  • Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics., Fradet Y, Cordon-Cardo C, Whitmore WF, Melamed MR, Old LJ, Cancer research, 1986
  • Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder., Huffman JL, Fradet Y, Cordon-Cardo C, Herr HW, Pinsky CM, Oettgen HF, Old LJ, Whitmore WF, Melamed MR, Cancer research, 1985
  • [The treatment of localized cancer of the prostate using radioactive iodine implants]., Fradet Y, Laverdière J, Beaudoin L, L'union medicale du Canada, 1985
  • [The use of multiparameter flow cytometry in the detection and evaluation of human bladder tumors]., Fradet Y, Tardif M, Parent-Vaugeois C, L'union medicale du Canada, 1985
  • Immunoanatomic dissection of the human urinary tract by monoclonal antibodies., Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF, Lloyd KO, Oettgen HF, Melamed MR, Old LJ, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 1984, 10.1177/32.10.6384360
  • Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies., Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore WF, Lloyd KO, Melamed MR, Old LJ, Proceedings of the National Academy of Sciences of the United States of America, 1984, 10.1073/pnas.81.1.224
  • Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies., Fradet Y, Roy R, Lachance JG, Noël R, Clinical nephrology, 1982
  • Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival., Roy R, Fradet Y, Lachance JG, Tissue antigens, 1981, 10.1111/j.1399-0039.1981.tb01371.x
  • Characterization of lymphocytotoxic antibodies in renal transplantation., Roy R, Lachance JG, Fradet Y, Hebert J, Transplantation, 1981, 10.1097/00007890-198101000-00008
  • Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans., Fradet Y, Simard J, Grose JH, Lebel M, Prostaglandins and medicine, 1980, 10.1016/0161-4630(80)90087-7
  • [Immunologic activities of lymphocytes in rats. IV. Chronologic functional variation of lymphocytes of the thoracic duct]., Fradet Y, McNicoll J, Daguillard F, L'union medicale du Canada, 1977
  • [Modulation of lymphocyte proliferation by serum factors and lipopolysaccharide], Fradet Y, Boncy J, Daguillard F, Annales d'immunologie, 1977
  • Regulation of in vitro lymphocyte responses. I. Adjuvant effect of lipopolysaccharide (LPS) on low-zone unresponsiveness to concanavalin A., Fradet Y, Roy R, Daguillard F, Cellular immunology, 1976, 10.1016/0008-8749(76)90157-x
  • Immunological activities of rat lymphocytes. II. Isolation of suppressor cells of the mitogenic response of rat thoracic duct lymphocytes., Tardieu M, Fradet Y, Daguillard F, Cellular immunology, 1975, 10.1016/s0008-8749(75)80012-8

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Amenan Prisca Nadege Kone - Post-doctorat - En cours
  • Vanessa Bussières - Maitrîse avec mémoire - En cours
  • Sébastien Le Batteux - Doctorat - En cours
  • Mohammad Balood - Doctorat - En cours
  • Fahimeh Aeineh Negin - Doctorat - En cours
  • Florin Constantin - Maitrîse avec mémoire - 2010/05
  • Laurence Bérubé Cooey - Maitrîse avec mémoire - 2012/01
  • Ehsan Dadvar - Maitrîse avec mémoire - 2014/01
  • Denise St-Onge - Maitrîse avec mémoire - 2016/05
  • Marjorie Besancon - Doctorat - 2017/09
  • Oscar Eduardo Molina - Maitrîse avec mémoire - 2018/05
  • Benjamin Vittrant - Doctorat - 2021/01
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine, local 4645
Québec (Québec) G1V 0A6
Canada

Renseignements - Secrétariat
418 656-2690
vdres@fmed.ulaval.ca

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs